Protagonist Therapeutics PTGX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.71M-304% | -$130.15M-147% | $45.91M— | $52.04M— | $56.19M— | ||
| $1.45M+74.7% | $1.28M+55.0% | $1.02M+6.9% | $892K-7.9% | $829K-14.1% | ||
| $46.69M+11.2% | $45.97M+22.4% | $44.37M+26.5% | $43.97M+38.9% | $42M+35.2% | ||
| $5.8M— | $4.03M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.66M— | ||
| $3.38M-18.0% | $2.41M-41.0% | $2.05M-47.8% | $3.21M— | $4.12M— | ||
| —— | —— | —— | —— | —— | ||
| -$18.79M— | -$21.02M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.26M-24.0% | $1.59M+17.3% | $1.76M+65.0% | $2.44M+253% | $1.66M+97.1% | ||
| $401.51M-47.9% | $546.59M-12.1% | $556.72M-8.0% | $662.27M+66.6% | $770.07M+237% | ||
| $535.35M+46.8% | $491.84M+52.0% | $444.6M+74.8% | $400.68M+66.0% | $364.77M+95.6% | ||
| —— | —— | —— | —— | -$399.96M-830% | ||
| —— | —— | —— | —— | —— | ||
| $34.8M+15.6% | $22.86M-11.6% | $24.06M+7.6% | $30.45M-33.2% | $30.1M-80.1% | ||
| —— | —— | —— | -$187.04M— | -$32.92M— | ||
| —— | $3.69M+141% | $3.15M— | $2.61M— | $2.07M— | ||
| $5.96M-37.6% | $7.22M-18.6% | $8.65M+15.9% | $9.8M+74.1% | $9.55M+93.7% | ||
| $5.8M— | $4.03M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.66M— | ||
| $3.38M-18.0% | $2.41M-41.0% | $2.05M-47.8% | $3.21M— | $4.12M— | ||
| —— | —— | —— | —— | -$300.04M-201% | ||
| $1.46M-29.0% | $1.59M-23.2% | $1.66M-25.7% | $1.97M-18.0% | $2.05M-12.0% | ||
| $535.35M+46.8% | $491.84M+52.0% | $444.6M+74.8% | $400.68M+66.0% | $364.77M+95.6% | ||
| —— | —— | —— | —— | —— | ||
| $34.8M+13.8% | $23.34M-11.8% | $24.54M+7.0% | $30.93M+160% | $30.58M+197% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $3.69M+141% | $3.15M— | $2.61M— | $2.07M— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Protagonist Therapeutics generate?
- Protagonist Therapeutics (PTGX) generated $317.6M in operating cash flow over the trailing twelve months.
- What is Protagonist Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Protagonist Therapeutics's free cash flow was $316.6M over the trailing twelve months, up 364.9% year over year.
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
